118 related articles for article (PubMed ID: 24999082)
1. Rectal perforation after two years of treatment with sunitinib for metastatic kidney cancer.
Bladé JS; Bourgouin S; Romeo É; Boudin L; de Jauréguiberry JP
Presse Med; 2014 Nov; 43(11):1293-5. PubMed ID: 24999082
[No Abstract] [Full Text] [Related]
2. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
Khan KH; Fenton A; Murtagh E; McAleer JJ; Clayton A
Tumori; 2012; 98(5):139e-142e. PubMed ID: 23235770
[TBL] [Abstract][Full Text] [Related]
3. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
[No Abstract] [Full Text] [Related]
4. Sunitinib and hypothyroidism.
Wolter P; Dumez H; Schöffski P
N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
[No Abstract] [Full Text] [Related]
5. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Yildiz I; Sen F; Basaran M; Ekenel M; Agaoglu F; Darendeliler E; Tunc HM; Ozcan F; Bavbek S
Jpn J Clin Oncol; 2011 Dec; 41(12):1380-7. PubMed ID: 22013228
[TBL] [Abstract][Full Text] [Related]
6. Fatigue with sunitinib-induced hypothyroidism.
Senior K
Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
[No Abstract] [Full Text] [Related]
7. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
8. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
9. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
[No Abstract] [Full Text] [Related]
10. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
11. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
Thiery-Vuillemin A; Mouillet G; Pouessel D; Barthelemy P; Caty A; Sebbagh S; Vanno YA; Laplaige P; Cheverau C; Ravaud A
Bull Cancer; 2014 Sep; 101(9):832-40. PubMed ID: 25295955
[TBL] [Abstract][Full Text] [Related]
12. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Rodríguez-Reimúndes E; Perazzo F; Vilches AR
Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in kidney cancer: 10 years of experience and development.
Nassif E; Thibault C; Vano Y; Fournier L; Mauge L; Verkarre V; Timsit MO; Mejean A; Tartour E; Oudard S
Expert Rev Anticancer Ther; 2017 Feb; 17(2):129-142. PubMed ID: 27967249
[TBL] [Abstract][Full Text] [Related]
14. Lower limbs erosions induced by sunitinib.
Kluger N; Chapelle A; Jacot W; Guillot B
Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
[No Abstract] [Full Text] [Related]
15. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
16. Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.
Massari F; Ciccarese C; Bimbatti D; Fantinel E; Modena A; Simbolo M; Brunelli M; Artibani W; Martignoni G; Scarpa A; Tortora G
Anticancer Drugs; 2015 Apr; 26(4):469-73. PubMed ID: 25569703
[TBL] [Abstract][Full Text] [Related]
17. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.
Porta C; Levy A; Hawkins R; Castellano D; Bellmunt J; Nathan P; McDermott R; Wagstaff J; Donnellan P; McCaffrey J; Vekeman F; Neary MP; Diaz J; Mehmud F; Duh MS
Cancer Med; 2014 Dec; 3(6):1517-26. PubMed ID: 25045157
[TBL] [Abstract][Full Text] [Related]
18. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
19. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
20. Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.
Hoshino Y; Hasegawa H; Ishii Y; Endo T; Ochiai H; Okabayashi K; Kaneko G; Mikami S; Mukai M; Oya M; Kitagawa Y
Int J Clin Oncol; 2012 Aug; 17(4):412-6. PubMed ID: 21927829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
